Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UNITED THERAPEUTICS Corp Director's Dealing 2017

Jun 9, 2017

30320_dirs_2017-06-09_6759e604-4cf7-4331-abff-e898b814f410.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UNITED THERAPEUTICS Corp (UTHR)
CIK: 0001082554
Period of Report: 2017-06-08

Reporting Person: ROTHBLATT MARTINE A (Director, Chairman & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-06-08 Common Stock M 1240 $30.75 Acquired 1380 Direct
2017-06-08 Common Stock M 937 $30.75 Acquired 660303 Indirect
2017-06-08 Common Stock S 400 $128.9625 Disposed 980 Direct
2017-06-08 Common Stock S 740 $129.808 Disposed 240 Direct
2017-06-08 Common Stock S 100 $130.56 Disposed 140 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-06-08 Stock Options $30.75 M 1240 Disposed 2017-12-31 Common Stock (1240) Direct
2017-06-08 Stock Options $30.75 M 937 Disposed 2017-12-31 Common Stock (937) Direct

Footnotes

F1: This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person.

F2: Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.

F3: This transaction was executed in multiple trades at prices ranging from $128.37 to $129.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $129.41 $130.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.